| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | NaN | NaN | NaN | 0 |
| Related party travel costs | NaN | NaN | NaN | 0 |
| General and administrative expenses | 573,539 | 838,472 | 386,951 | 5,027,071 |
| Research and development expenses | 467,797 | 1,296,209 | 759,525 | 42,839 |
| Total operating costs | 1,041,336 | 2,134,681 | 1,146,476 | 5,069,910 |
| Interest income | 51,644 | 73,488 | 44,182 | 1,362 |
| Interest expense | 1,255 | NaN | NaN | 1,342 |
| Total other income, net | 50,389 | NaN | NaN | NaN |
| Net loss | -990,947 | -2,061,193 | -1,102,294 | -5,069,890 |
| Basic EPS | -0.03 | -0.06 | -0.03 | 0.17 |
| Diluted EPS | -0.03 | -0.06 | -0.03 | 0.17 |
| Basic Average Shares | 34,380,971 | 34,440,634 | 32,398,906 | 30,010,165 |
| Diluted Average Shares | 34,380,971 | 34,440,634 | 32,398,906 | 30,010,165 |
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)